Analysts Have Conflicting Sentiments on These Healthcare Companies: Celldex (CLDX) and Intercept Pharma (ICPT)
According to TipRanks.com, Howerton s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Celldex has an analyst consensus of Strong Buy, with a price target consensus of $66.50, which is a 176.6% upside from current levels. In a report issued on July 1, SVB Securities also maintained a Buy rating on the stock with a $68.00 price target.
See Insiders’ Hot Stocks on TipRanks >>Intercept Pharma (ICPT) In a report released today, Thomas Smith from SVB Securities maintained a Hold rating on Intercept Pharma, with a price target of $21.00. The companys shares closed last Thursday at $15.16.According to TipRanks.com, Smith has 0 stars on 0-5 stars ranking scale with an average return of
Intercept Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $28.88, an 116.3% upside from current levels. In a report released yesterday, Oppenheimer also maintained a Hold rating on the stock with a $16.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Read More on CLDX:- Analysts Offer Insights on Services Companies: Carnival (CCL) and Churchill Downs (CHDN)
- Analysts’ Opinions Are Mixed on These Technology Stocks: AT&T (T) and Microsoft (MSFT)
- Analysts Are Bullish on These Financial Stocks: Agree Realty (ADC), Digital Realty (DLR)
- Deutsche Bank Keeps Their Buy Rating on Vitesco Technologies Group AG (VTSCF)
- Deutsche Bank Maintains a Hold Rating on Continental Aktiengesellschaft (CTTAF)
Paid Post: Content produced by TipRanks. The Globe and Mail was not involved, and material was not reviewed prior to publication.
